Novo Nordisk enters gene-editing therapy collaboration with US biotech Life Edit Therapeutics
A collaboration centered on seven development programs may trigger milestone payments up to USD 1.9bn. (Updated)
by christopher due karlsson, translated by daniel pedersen
Novo Nordisk announced on Wednesday that it has established a multi-target collaboration with US-based Life Edit Therapeutics. Milestone payments under the deal could reach as much as USD 1.9bn in total.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings participates in divestment of VectivBio
For subscribers
